Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma

Abstract

To our best knowledge, our study showed for the first time a significant association between HER2 expression and the type of GBM, with subsequent influence on survival rate. GBM with low-HER2 expression are more likely to be secondary GBM, carrying a better prognosis than de novo GBM.

Cerebral Blood Volume Measurements by Perfusion-Weighted MR Imaging in Gliomas: Ready for Prime Time in Predicting Short-Term Outcome and Recurrent Disease?

“…The results of ROC analysis of mean and maximum CBV and rCBV values as predictors of PFS 12 were not statistically significant when the oligodendrogliomas and oligoastrocytomas (separately and together) were included (P Ͼ .15). For astrocytomas only, the CBV max threshold of Ͼ4.2 was found to be a significant cutoff value for recurrence/progression prediction with 77.8% sensitivity and 94.4% specificity (P ϭ .0001), whereas the cutoff value of Յ3.8 was a significant predictor for 1-year survival (93.7% sensitivity, 72.7% specificity, P ϭ .0002).…”

“…ROC analysis of the WHO grading system as a predictor of PFS 12 showed that WHO grade Ͼ2 demonstrated significant (P ϭ .0001) sensitivity (88.9%) and specificity (72.2%) in predicting recurrence (Fig 4). The predictability of 1-year survival based on the histopathologic grading was also statistically significant (sensitivity, 81.2%; specificity, 90.9%; P ϭ .0002).…”

“…PFS was retrospectively calculated from the medical records. We determined the number of patients with a PFS of less or more than 12 months (PFS 12 ).…”

“…11 Our intention was to conduct an investigation without the bias introduced by patient classification according to the histopathologic tumor grade. We designed a study with the primary objective of examining the role of MR imagingϪderived rCBV values in predicting prognosis in a setting that includes the following: 1) a population of all patients with gliomas, 2) a short-term end point (1-year progression-free survival [PFS] rate) because it seems to be critical for dedifferentiation of astrocytomas from anaplastic astrocytomas or glioblastomas and for survival time in patients with glioblastomas, 12 and 3) no patient stratification according to the WHO grade. Our main hypothesis was that rCBV values are a reliable predictor for 1-year PFS in all patients with astrocytomas, better or complementary to the histopathologic grade.…”

Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice

“…10 This receptor is well suited for this purpose because it is expressed in a considerable (15-80%) fraction of HGGs 11,12 and is a pejorative prognosis factor for several cancers including brain tumors. [13][14][15] Notably, HER2 is not expressed in adult central nervous system; 16 hence, it is a highly specific target for oncolytic virotherapy. The study was conducted in an immunodeficient mouse strain (NOD/ SCID) in order to better challenge the safety of the recombinant virus.…”